Keytruda
Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma
Pressure score
33
Momentum score
5
Why This Matters
Bristol Myers Squibb is a direct competitive threat because it has a development-stage program in Oncology · Melanoma (Keytruda) and could narrow Bristol Myers Squibb's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Stage unknown
- Stage gap
- Stage comparison unavailable — competitor development phase not fully evidenced.
- Market share risk
- Share risk is emerging — primarily strategic positioning rather than immediate revenue displacement.
Strategic Action
Align with signal posture: investigate. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
Gene Amplification Adjacent to F3 Linked to Poor Outcomes in Pancreatic Adenocarcinoma
Oncology · Pancreatic Adenocarcinoma · Other · These findings suggest potential biomarkers for poor prognosis in pancreatic adenocarcinoma, which could influence treatment strategies and patient management.
Source: ClinicalTrials.gov
View source documentRelated Signal
Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
Open signalCompetitor Position
Competitor race
Pressure ranking for this signal's competitive set
Position: #2 of 2
Merck
1 competitive finding
Top program: Keytruda
- Pressure
- 58
- Momentum
- 63
- Threat
- direct competitor
- Stage
- Approved
58MerckMediumKeytruda·Approved
Bristol Myers Squibb
2 competitive findings
Top program: Keytruda
- Pressure
- 33
- Momentum
- 5
- Threat
- direct competitor
- Stage
- Stage unknown
33Bristol Myers SquibbLowKeytruda·Stage unknown